Sorry, you need to enable JavaScript to visit this website.

Competitive Grants Program

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.

Sign Up for Alerts Details
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    The Enhancement of Management of breast cancer in French speaking Sub-Saharan African Countries
    Release Date:
    Partner: AMFROM
    Review Process: Expert Review Panel
    Translation: French (link)
    Quality Improvement Oncology Benin, Congo, The Democratic Republic, Mali, Senegal, Togo
    Improving Atopic Dermatitis and Alopecia Areata Quality of Care to Standardize Management
    Release Date:
    Partner: Beijing Guangda Precision Medicine Research Center
    Review Process: Expert Review Panel
    Quality Improvement Inflammation & Immunology China
    Optimizing Antimicrobial Stewardship Program in Saudi Arabia
    Release Date:
    Review Process: Expert Review Panel
    Quality Improvement Inflammation & Immunology Saudi Arabia
    Invasive Mold Infections (IMI) - Real-World Evidence from Treatment Outcomes with Isavuconazole
    Release Date:
    Review Process: Pfizer Internal
    Research Inflammation & Immunology Australia, Germany, Israel, Italy, Spain, Switzerland
    PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology USA
    Pediatric pneumococcal carriage and serotype distribution surveillance: prospective studies in South-East Asia, 2025-2026
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines India, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Vietnam
    Advancing Health Care Professionals’ knowledge and understanding of adult and maternal vaccination against respiratory infection
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Finland, Greece, Hungary, Ireland, Israel, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Slovenia, Ukraine
    Review and analysis of serotype distribution and burden of pneumococcal disease in children younger than 5 years – Post vac era
    Release Date:
    Review Process: Pfizer Internal
    Research Vaccines Burkina Faso, Congo, The Democratic Republic, Cote D'ivoire, Ethiopia, Ghana, Mozambique, Pakistan, Senegal, Sudan, Tanzania, United Republic of
    The Clinical Application of ATM-AVI in Patients with CRE Infections, including MBL-Producing CRE
    Release Date:
    Review Process: Pfizer Internal
    Research Hospital China, Hong Kong
    COVID-19 Disease Burden on the High Risk Population
    Release Date:
    Review Process: Pfizer Internal
    Education Vaccines All
    New Research Areas to Improve Diagnosis and Treatment of Inflammatory Bowel Disease
    Release Date:
    Review Process: Expert Review Panel
    Research Inflammation & Immunology USA
  • Title
    Grant Type
    Focus Area
    Country
    Application Due Date
    Education for Improving Appropriate Diagnosis and Treatment for Venous Thromboembolism
    Release Date:
    Review Process: Pfizer Internal
    Education Internal Medicine Japan
    Education and Support for Patients with Locally-Advanced or Metastatic Bladder Cancer
    Release Date:
    Partner: Merck KGaA, Darmstadt, Germany and EMD Serono
    Review Process: Pfizer Internal
    Education Oncology USA
    Pre-clinical & Translational Research in Multiple Myeloma
    Release Date:
    Review Process: Pfizer Internal
    Research Oncology Canada, USA
    Management of Patients with BRAF-mutant metastatic colorectal cancer
    Release Date:
    Review Process: Pfizer Internal
    Education Oncology Canada, USA
    Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare Disease
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Rare Disease All
    Promotion of Smoking Cessation Treatment in General Practice
    Release Date:
    Review Process: Pfizer Internal
    Education Internal Medicine Japan
    2021 Growth Hormone Research (All countries except for the United States)
    Release Date:
    Review Process: Pfizer Internal
    Research Rare Disease All
    Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain
    Release Date:
    Partner: Lilly
    Review Process: Pfizer Internal
    Education Internal Medicine All
    NSCLC Therapy Management for Optimal Outcomes
    Release Date:
    Review Process: Pfizer Internal
    Quality Improvement Oncology Andorra, Austria, Belgium, Canada, Denmark, France, Germany, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Malta, Monaco, Netherlands, Norway, Portugal, San Marino, Spain, Sweden, Switzerland, USA, United Kingdom
    Clinical Research Capability Development
    Release Date:
    Review Process: Pfizer Internal
    Education Internal Medicine China
    Educational Program to Increase Awareness and Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    Release Date:
    Review Process: Pfizer Internal
    Education Rare Disease China
    Advances in Moderate-to-Severe Atopic Dermatitis for Dermatologists and Allergists
    Release Date:
    Review Process: Pfizer Internal
    Education Inflammation & Immunology USA